乙醯左旋肉鹼 Acetyl-L-Carnitine × 認知功能

結論:證據支持但有警示

The evidence for acetyl-L-carnitine improving cognitive function is weak and inconsistent.

C 🟠 C 薄弱證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

The evidence for acetyl-L-carnitine improving cognitive function is weak and inconsistent. The often-cited 2003 meta-analysis (21 RCTs, 1204 participants in MCI/mild-AD) found only a small effect (ES ~0.20), and it rests on old, heterogeneous, largely manufacturer-era trials with undisclosed funding. The contemporaneous 2003 Cochrane review found benefit only on the subjective Clinical Global Impression scale, no effect on objective cognitive or functional outcomes, and explicitly advised against routine clinical use; the 2017 Cochrane review found no measurable effect in cognitively healthy adults on very-low-quality evidence. EFSA formally rejected the ALCAR cognitive-function health claim (ID 1432, no cause-and-effect relationship), and no major clinic (Mayo, Cleveland, Harvard) or neurology society (Alzheimer's Association, AAN) endorses ALCAR for cognition. A Grade C is warranted: there is a small, plausible signal confined to clinical (MCI/mild-AD) populations, but it does not survive objective endpoints, is contradicted in healthy adults, and lacks any regulatory or society endorsement.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.47
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
82%
證據方向一致性高
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.50
L11 AI 複核獨立判讀
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.472
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease
PMID: 12598816 2003 統合分析 n = 1,204
結論:Across 21 pooled RCTs, ALCAR showed a significant but small advantage over placebo for the integrated summary effect (ES 0.201, 95% CI 0.107-0.295) and for CGI-CH (ES 0.32, 95% CI 0.18-0.47); benefit appeared by 3 months and increased over time, and ALCAR was well tolerated.
效應量:ES 0.201 (integrated summary); ES 0.32 (CGI-CH) - both small
前往 PubMed
Acetyl-L-carnitine for dementia (Cochrane systematic review)
PMID: 12804452 2003 Cochrane SR
結論:Reviewers found a benefit on Clinical Global Impression at 12 and 24 weeks but no benefit on objective cognitive or functional outcomes; concluded there is no evidence to recommend routine clinical use of ALCAR for dementia.
🟢 高品質 效應量:No effect on objective cognitive measures; CGI benefit only
前往 PubMed
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update
PMID: 32408706 2020 系統性回顧
結論:Results across trials are inconsistent; some studies show benefit in AD and MCI while others do not, and the role of ALCAR in dementia remains under debate. Authors conclude further studies with homogeneous samples and longitudinal assessment are needed before systematic clinical application.
效應量:inconsistent; no robust pooled estimate
前往 PubMed
L-carnitine for cognitive enhancement in people without cognitive impairment (Cochrane systematic review)
PMID: 28349514 2017 Cochrane SR n = 200
結論:Only 2 small RCTs were eligible; evidence was very low quality and showed no effect of L-carnitine on reaction time, vigilance, immediate memory or delayed recall. Reviewers could not draw conclusions about efficacy or safety for cognitive enhancement in healthy people.
🟢 高品質 效應量:No measurable effect in healthy adults
前往 PubMed

L4a US FDA
謹慎
NUTRIENT SUPPLEMENT [21 CFR 170.3(o) technical effect — substance: Carnitine / L-carnitine / Levocarnitine, CAS 541-15-1] 來源↗
L4b EU EFSA
反對
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,L-肉鹼(L-carnitine)總含量不得高於 2 公克。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

台灣社群幾乎沒有乙醯左旋肉鹼專門用於「認知功能」的鄉民實測。少數 PTT 健身板(MuscleBeach)討論把它當減脂/抗疲勞補劑,對效果偏保守(『輔助效果因人而異』);認知/補腦的社群實測多指向魚油、磷脂醯絲胺酸(PS)、銀杏與市售複方(蓉憶記、愛因思坦),ALCAR 屬冷門題目,中文內容多為保健品 SEO 與 iHerb 代購頁,非匿名辯證。

💬社群實感

無共識(台灣 PTT/Dcard/Mobile01 幾乎無 ALCAR 用於認知功能的在地實測;少數討論集中於減脂/抗疲勞情境且評價保守,補腦實測多指向魚油/PS/銀杏與市售複方而非單方 ALCAR)

破解迷思 社群最常見的 3 個誤解
事實把「乙醯左旋肉鹼(ALCAR)」與一般「左旋肉鹼(L-carnitine)」混為一談(社群有人明確指出兩者不同),誤以為減脂用的左旋肉鹼即可補腦
事實誤以為 ALCAR 是強效益智藥能直接提升認知/記憶(中文宣稱多源自保健品 SEO 與商品頁,非台灣社群真實回饋)
事實把抗疲勞/運動恢復的效果直接等同於認知提升,混淆兩種不同用途
🩹 社群通報的副作用
  • 腸胃不適(反胃/噁心/腹瀉,多見於商品頁與衛教文,非台灣社群多人實測回饋)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • Nutricost ALCAR(iHerb/Amazon 代購,商品頁能見度高於社群討論)
  • Now Foods / California Gold Nutrition 等 iHerb 代購品牌(市場習慣以海外代購為主,無強勢台灣本土品牌)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

NOW Foods, Acetyl-L-Carnitine, 500 mg, 100 Veg Capsules

代表來源 ↗
L10b · TFDA 法定身份 官方認定

形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,左旋肉鹼總含量不得高於2公克

來源 ↗

  • 規律身體活動
  • 高血壓的妥善控制
  • 戒菸
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v24 engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-acetyl-l-carnitine-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-cognitive-function-INT-acetyl-l-carnitine-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "乙醯左旋肉鹼能改善認知功能",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}